Citations

Mayo Clinic

Showing 10 of 108537 citations.

Abstract 16962: The Genetic Basis of Hypercholesterolemia in a Community-Based Cohort
Jose, Merin, Kochan, David C., Kullo, Iftikhar J.

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16962 Get It

Introduction: Prior reports of the genetic etiology of hypercholesterolemia are affected by referral bias, inclusion of individuals with secondary hypercholesterolemia and variability in identifying pathogenic variants. We sought to assess the prevalence of monogenic and polygenic etiologies in a community based cohort of adults with primary hypercholesterolemia (LDL-C ≥155 mg/dL after excluding secondary causes). Methods: We identified 1719 individuals aged 18-70 years with primary hypercholesterolemia from SE Minnesota. The Dutch Lipid Clinic Network (DLCN) score was ascertained by an electronic health record (EHR) based algorithm followed by manual review. Familial hypercholesterolemia (FH) was considered present with a DLCN score ≥6 whereas a DLCN score of 3-5 was considered possible FH. Participants underwent sequencing of FH genes ( LDLR, APOB, PCSK9 ) and genotyping of 12 SNPs known to be associated with LDL-C. Rare (frequency <0.1%) and putatively functional variants were identified and pathogenicity was assigned based on the ACMG guidelines using relevant database, literature and EHR review. A polygenic score (PGS) for LDL-C (derived from 12 SNPs) >90 th percentile was considered an indicator of polygenic etiology. Results: A pathogenic/likely pathogenic variant (16 in LDLR , 1in APOB and 2 in PCSK9 ) was present in 24 (1.3%) individuals, a PGS >90 th percentile was present in 265 (15.4%) and 4 (0.2%) had both a monogenic and polygenic etiology. The overall prevalence of an identifiable genetic etiology was 17%. Based on clinical criteria the overall prevalence of FH (DLCN ≥6) was 7.0% (6.1% probable and 0.9% definite) and that of possible FH was 30.0%. In the possible, probable and definite FH categories, a monogenic etiology was present in 2.4%, 9.5% and 26.7% and a polygenic etiology in 19.1%, 21.0% and 13.3% respectively. 52.0% of those with a monogenic etiology and 9.7% of those with a polygenic etiology met the DLCN criteria for FH. Conclusions: This study provides for the first time estimates of monogenic and polygenic etiology of hypercholesterolemia in adults from the community, excluding cases of secondary hypercholesterolemia and using standardized methods of variant annotation.
Abstract 16942: Reduced Gastrointestinal Bleeding in Patients With Improved Left Ventricular Function After Left Ventricular Assist Device Implantation
Mandawat, Aditya, Mandawat, Anant , Vijayvargiya, Priya , Karra, Ravi

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16942 Get It

Introduction: Gastrointestinal bleeding (GIB) after continuous-flow left ventricular assist device (CF-LVAD) implantation is common, with an incidence estimated at 18-40% per year. While the pathophysiology of GIB in these patients is unclear, physiologic changes related to the absence of pulsatility may account for the high rates of GIB seen in these patients. Hypothesis: Improved left ventricular (LV) function (increased myocardial pulsatility) after LVAD implantation may be associated with decreased rates of GIB. Methods: We studied 119 consecutive patients with CF-LVADs implanted between March 2006-November 2016 who received serial transthoracic echocardiograms (TTE), including at least one pre-implant and one post-implant TTE. Left ventricular ejection fraction (LVEF) was assessed by experienced readers, with a kappa statistic between readers >0.90. Improved LV function was defined as an improvement of at least 7% between the pre-implant LVEF and the best post-implant LVEF obtained with 9 months of the implantation date. Similarly, worsening LV function was defined as a decrease of at least 7%. Primary GIB was defined using INTERMACS adverse event criteria. Patients were followed until transplantation, device complication requiring explantation, or death. Results: The study sample was 58±12 years old, 72% male, and 63% Caucasian. Hemoglobin at implantation was 11±2 g/dL. Maximum LV recovery was seen a median of 103 (IQR 49-158) days after LVAD implantation. Improved LV function occurred in 25 (21%) patients, while LVEF remained stable or worsened in 94 (79%) of patients. When compared with patients whose LVEF remained stable or worsened, patients with improved LV function were more likely to be female (p=0.05). GIB occurred in 29 patients (24%). Improved LV function was associated with a significantly decreased risk of GIB (Figure; p=0.05). Conclusions: Improved LV function is seen in one-fourth of patients and is associated with a significantly decreased risk of GIB following CF-LVAD implantation.
Abstract 16940: Frailty Predicts Mortality Among Patients Referred for Cardiac Catheterization
Kanwar, Amrit , Gulati, Rajiv , Sabbagh, Abdallah El , Lennon, Ryan J. , Singh, Mandeep , Widmer, R. Jay , Al‐Hijji, Mohammed , Lerman, Amir

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16940 Get It

Introduction: Survivorship needs to be comprehensively evaluated amongst older adults. We examined follow-up mortality in patients referred to cardiac catheterization laboratory by prospectively examining frailty. Methods: Frailty in 923 patients ≥55 years was determined using Rockwood’s deficit index. The frailty deficit was based on symptoms, signs, disabilities, diseases, and laboratory measurements. The number of deficits was expressed as a proportion of the total measured deficits. Frailty index was grouped into <0.10 (control), 0.10-<0.20, 0.20-<0.30, 0.30+ and age- and gender-adjusted follow-up mortality was determined using a Cox proportional hazards model. Results: There were 180 (20%) with frailty index <0.10, 348 (38%) in 0.10-<0.20, 215 (23%) in 0.20-<0.30 and 177 (19%) with an index of 0.30 or higher. Patients with a frailty index of 0.30+ were significantly older than those with an index <0.10 (75 ± 10 vs 67 ± 8 years; p<0.001) and more likely to be women (50% vs 20%; p<0.001). Patients with frailty index ≥0.20 and ≥0.30 had a significantly higher mortality risk (HR 3.95, 95% CI 1.51-10.3 and HR: 10.3, 95% CI 4.11-25.7, respectively) on follow-up which remained significant following adjustment for age and gender (HR 3.20, 95% CI 1.21-8.45 and HR: 7.99, 95% CI 3.13-20.4). Conclusions: Among older adults refereed to catheterization laboratory, frailty deficit index predicts follow-up mortality.
Abstract 16933: A Decision Aid for the Use of PCSK9 Inhibitors in Patients With Familial Hypercholesterolemia
Shaw, Kevin, Hargraves, Ian , Farwati, Medhat , Montori, Víctor M. , Kullo, Iftikhar J.

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16933 Get It

Introduction: Familial Hypercholesterolemia (FH) is a common inherited disorder of lipid metabolism. FH patients are at an increased risk of atherosclerotic cardiovascular disease (ASCVD) due to elevated low-density lipoprotein cholesterol (LDL-C) levels. Patients with FH may not reach target LDL-C levels despite maximally tolerated statin (±ezetimibe) therapy (MTT). The AHA scientific statement on FH highlighted the need for developing decision aids (DAs) to facilitate shared decision making (SDM) regarding additional therapy including PCSK9 inhibitors. Methods: A user-centered design process was initiated to understand FH treatment decisions and to develop prototype interventions. Patients with FH had their diagnosis confirmed by genetic testing. Encounters between FH patients and health care providers were video recorded and analyzed to assess how decisions are made regarding lipid lowering therapy. Nine encounters were recorded: 3 with a genetic counselor and 6 with an FH specialist. Informed by clinical encounters and literature review, we developed content for a DA related to available therapeutic options for FH patients on MTT. Results: A prototype online DA was created to support in-encounter discussion of a patient’s risk of adverse cardiovascular events and which therapies may be best suited to the patient (Figure). 5 and 10-year ASCVD risk is estimated using the SAFEHEART Risk Score (SRS). Risk is communicated in numbers using a 100-person icon array and the language “Out of 100 persons like you...”. Therapeutic options include watchful waiting, bile acid sequestrants, and PCSK9 inhibitors. For each option, the degree of risk reduction, costs, and side effects are presented. The tool is currently being refined by analyzing additional encounters with FH patients. Conclusion: We developed an interactive prototype DA to facilitate SDM for FH patients on MTT. After further iterative testing the tool will be deployed in the electronic health record.
Abstract 16921: Noninvasive Quantification of Myocardial Elasticity in Patients With Hypertrophic Cardiomyopathy
Anupraiwan, Orawan, Pislaru, Sorin V. , Pellikka, Patricia A. , Pislaru, Cristina

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16921 Get It

Introduction: Hypertrophic cardiomyopathy (HCM) is associated with excessive left ventricular (LV) hypertrophy (LVH), myocyte disarray and expansion of interstitial collagen. These factors alter mechanical properties of the myocardial tissue. Intrinsic velocity propagation (iVP) of myocardial stretch is a new validated measure of myocardial elasticity. Hypothesis: iVP in left ventricular (LV) myocardium of patients with HCM will be increased compared to normal subjects. Methods: We studied prospectively 100 subjects: 42 with HCM (age 57 ± 14 years; 79% with asymmetric septal LVH) and 58 normal controls without cardiovascular disease (age 48 ± 13 years). Patients had comprehensive transthoracic echocardiography and cardiac magnetic resonance imaging (MRI; n=29). iVP was measured throughout the LV myocardium during late diastole using ultra-high frame rate tissue Doppler imaging (350-460 fps) (6 LV walls, 3 standard apical views). Chamber stiffness (CS) was evaluated from end-diastolic pressure-volume relationship (EDPVR) estimated noninvasively by the single-beat method (EDP=αV β ). End-diastolic pressure (EDP) was estimated from E/e’. Results: LV ejection fraction was normal in both groups (HCM: 68 ± 7%; Controls: 65 ± 5%). Myocardial stiffness by iVP was markedly higher in HCM vs. controls (Fig.A, left panel). This was confirmed by EDPVRs, which were steeper and shifted leftward (Fig. B, left). The slope (β, load-independent) of EDPVR and CS (dP/dV) were higher and LV capacitance (V 30 , estimated volume at 30 mmHg EDP) was lower in HCM (Fig. B, right) and correlated significantly, though weakly, with iVP (β: r = 0.41; CS dP/dV: r = 0.48; EDP: r = 0.61; p<0.002 for all). Patients with apical variant had lower levels of global iVP compared to patients with predominant septal LVH and diffuse concentric LVH (Fig. A, right). Conclusions: Myocardial stiffness measured noninvasively by the intrinsic wave method is highly abnormal in HCM. This novel approach allows mapping of myocardial elasticity of the entire left ventricle and shows promise to become a clinical tool for evaluation of patients with diastolic tissue abnormalities.
Abstract 16901: Utilizing In Silico Pathogenicity Prediction Tools and Heterologous Expression Patch Clamp Studies to Identify Bona Fide Pathogenic KCNH2 Variants Among Publically Available Exomes Derived From Subjects Withou
Mattivi, Connor L. , Ye, Dan , Tester, David J. , Clemens, Daniel J. , Giudicessi, John R. , Ackerman, Michael J. , Zhou, Wei

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16901 Get It

Introduction: Loss-of-function (LOF) and gain-of-function (GOF) pathogenic variants in the KCNH2 -encoded Kv11.1 potassium channel cause type 2 long QT syndrome(LQT2) and type 1 short QT syndrome (SQT1), respectively. Given the prevalence of KCNH2- mediated heart disease (1 in 8000 for LQT2,1 in 100,000 for SQT1) and the reduced penetrance/variable expressivity seen in LQTS and SQTS, large databases such as the Genome Aggregation Database (gnomAD, n=141,352 individuals) might harbor subjects with unidentified LQT2/SQT1-causative mutations. Objective: To determine which “ultra-rare” KCNH2 missense variants (MVs) in gnomAD are most likely to be LQT2- or SQT1-causative. Methods: A list of gnomAD-derived MVs in KCNH2 was compiled. The frequency of each MV in gnomAD was assessed. Each MV was analyzed by 8 in silico pathogenicity prediction tools. MVs that were seen once in gnomAD and predicted damaging by all 8 tools were considered possible LQT2/SQT1-causative MVs worthy of functional validation via whole-cell patch clamp. Results: Overall, 233/474 (49%) of gnomAD KCNH2 MVs were seen in just 1 of >140,000 subjects. Of these, 2 (0.4%) MVs (S320W, S379Y) were predicted damaging by 8 in silico tools. Both S320W and S379Y localize to the N-terminus of the Kv11.1 potassium channel. There was no significant change in peak or tail current density between heterozygously expressed KCNH2-S320W (n=13, p=NS) and KCNH2-WT (n=13). However, heterozygous KCNH2-S379Y (n=12) produced a marked increase in peak current density across the range -30 mV to +20 mV and shifted the V 1/2 of activation by -17 mV (p < 0.001). Also, tail current density of S379Y channels significantly increased across the range -20 mV to +20 mV and the V 1/2 of deactivation shifted by -26 mV (p < 0.001). Conclusion: With this stringent requirement of ultra-rarity, universal prediction of damaging impact, and functionally abnormal electrophysiological properties, one SQT1-causative pathogenic variant in gnomAD was identified consistent with the predicted frequency of SQTS. The search continues among the remaining 32 ultra-rare MVs in KCNH2 where at least 75% of the in silico tools predicted deleterious impact of the MV to find the 15-20 subjects in gnomAD’s population who ought to have an LQT2-causative MV.
Abstract 16865: Debunking the Concept That the “Metabolically Obese Normal Weight” Phenotype is Independent of Fat: It is All About Central Obesity
Saeidifard, Farzane , Homolka, Martin , Allison, Thomas G. , Bonikowske, Amanda R. , Medina‐Inojosa, José R. , Batsis, John A. , Maugeri, Andrea , Vinciguerra, Manlio , López-Jiménez, Francisco

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16865 Get It

Background: The Metabolically Obese Normal Weight (MONW) phenotype has been described as a unique subgroup of individuals with metabolic dysregulation similar to obese individuals, but not considered obese per se . In theory, these individuals have an adiposity-independent substrate predisposing them to metabolic dysregulation. We tested whether central obesity explains the metabolic abnormalities in persons with MONW in a prospective population-based cohort in the Czech Republic. Methods: We used data from Kardiovize Brno 2030 study, a prospective community-based cohort in Central Europe. We defined obesity using World Health Organization categories for body mass index (BMI) and central obesity by waist circumference (WC≥ 94 cm in men and ≥ 80 cm in women). Metabolically obese (MO) was defined using AHA criteria by having three or more of the following: Hypertriglyceridemia (≥ 1.7 mmol/l); HDL cholesterol level <1.0 mmol/l in men or <1.3 mmol/l in women; elevated blood pressure (systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg) or antihypertensive drug treatment or history of hypertension; elevated fasting plasma glucose ≥ 5.6 mmol/l; or drug treatment and central obesity. Results: Of the 2,056 participants (46% men; mean age= 47.2 years, SD=11.2) included in the current analysis, 975 (47.4%) had normal weight and 696 (33.8%) were overweight. Prevalence of MO in the overall sample was 20.6% (n=424), 3.7% (n=36) among those with normal BMI and 9.9% (n=204) among overweight individuals. From the 36 subjects with MONW, 33 (91.6%) had central obesity by WC, while 201/204 (98.5%) with metabolically obese overweight, had central obesity by WC. Remarkably, in a subgroup of people with no metabolic obesity factors nobody had central obesity, see Figure . Conclusions: Metabolic dysregulation in people labeled as MONW can be explained by excessive visceral adiposity and not by an inherent predisposition, independent of adiposity.These findings underscore the importance of identifying central obesity in clinical practice even if BMI is below the obese criteria.
Abstract 16833: Long-Term Outcomes and Complications of Anticoagulant Therapy for Bioprosthetic Valve Thrombosis in a Large Matched-Cohort Study
Petrescu, Ioana, Connolly, Heidi M. , Egbe, Alexander C. , Ionescu, Filip , Nkomo, Vuyisile T. , Pellikka, Patricia A. , Pislaru, Cristina , Pislaru, Sorin V.

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16833 Get It

Introduction: Bioprosthetic valve thrombosis (BPVT) is a well-recognized cause of prosthetic dysfunction. Anticoagulation restores prosthetic valve gradients, but long term outcomes and complications from therapy are unknown. Objectives: To define the complications and long-term outcomes of anticoagulant therapy for BPVT. Methods: Retrospective matched cohort study of patients treated with warfarin for presumed BPVT at a single center from 1999 to 2016. Controls with normal bioprostheses by echocardiography were matched 2:1 for age at implantation, gender, prosthetic valve position, and type of prosthesis (porcine / pericardial). Results: A total of 83 presumed BPVT patients (40 aortic, 21 mitral, 18 tricuspid, and 4 pulmonary) and 166 controls were included. Age at BPVT diagnosis was 60±19 yrs (41±41 months post implantation); 45 (54%) were male. Transvalvular gradients returned to baseline in 63 (76%) of the patients, after 5±4 months of warfarin; 60 (72%) patients were maintained on warfarin indefinitely. Recurrent BPVT was seen in 13 (16%) patients, 33±31 months after initial therapy. When compared to controls, warfarin-treated BPVT patients had similar incidence of stroke [4(5%) vs 5 (3%), p=0.49], peripheral embolic events [4(5%) vs 10 (6%), p=0.78)], and death [12 (14%) vs 28 (17%), p= 0.72] (Figure, left panel), but more bleeding requiring transfusion [18 (22%) vs 3 (2%), p<0.0001]. Presumed BPVT patients more often required surgical or percutaneous valve re-replacement (Figure, center panel); this difference persisted even when comparing only patients with confirmed BPVT (those who responded to anticoagulant therapy) vs. their matched controls (Figure, right panel). Conclusion: Warfarin anticoagulation for presumed BPVT is successful in the majority of patients, without increase in stroke, peripheral embolism or death, but at the cost of excess bleeding. Recurrent BPVT occured in 16% of patients. Importantly, patients with BPVT required more often valve re-replacement. This finding suggests that anticoagulant therapy does not fully restore prosthetic valve durability, and that BPVT patients should be closely monitored.
Abstract 16802: Intermittent Pneumatic Compression for Peripheral Artery Disease and End Stage Renal Disease to Improve Quality of Life and Functional Limitations
Fratti, Juan Del Cid , Ayub, Muhammad Talha , Al‐Ogaili, Ahmed , Sleiman, Jose , Hart, Peter D. , Tafur, Alfonso , Rios, Luis H. Paz , Torres, Christian , Fuentes, Harry E , Hart, Peter

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16802 Get It

Background: Peripheral artery disease (PAD) is a prevalent condition affecting one in four patients with end stage renal disease (ESRD). Intermittent pneumatic compression (IPC) has proven benefits in PAD. We are conducting a trial testing the utility of IPC in the ESRD population by assessing the improvement in quality of life (QOL), functional limitation and walking performance from PAD-related symptoms. We aim to present our pilot results. Methods: Prospective single cohort study undergoing recruitment of outpatients at the hemodialysis (HD) unit of John H. Stroger Hospital. The calculated sample size is 78. PAD is confirmed by ankle-brachial index (ABI) and demographics obtained from interview and chart review. At baseline and post intervention, a Six-minute Walk Test (6MWT), Peripheral Artery Questionnaire (PAQ) and Walking Impairment Questionnaire (WIQ) are administered. The IPC device (Bio Arterial Plus) is used for intervention during HD. We present continuous variables as median (IQR) and categorical variables as percentage. Wilcoxon signed rank test was performed for comparison of results. Results: So far, 9 patients have completed intervention for the pilot study, 44% are men, the majority hispanic (66%), with age 48 (41-63) years. At baseline 66% of ABI were abnormal, all due to non-compressible PAD 1.46 (1.20-1.62). All patients have HTN, 44% diabetes, 33% hyperlipidemia and 33% heart failure. The median time of intervention is 70 (60-83) days. There was a significant difference in QOL measured by the WIQ (Fig.1), PAQ physical limitation (p=0.011), and PAQ social limitation (p=0.018). Although there was a trend towards benefit, no statistical difference was found on rest of objective and subjective measured parameters (p>0.05) Conclusions: Preliminary, IPC shows to improve many subsets of QOL in patients with ESRD and PAD. Given the small sample, improvement of walking distance remains elusive but with trends towards benefit.
Abstract 16736: Etiology of Sudden Cardiac Arrest in Young Primary and Referral Populations: The Mayo Clinic Experience
Rodriguez-Cartagena, Luis G, Giudicessi, John R. , Ackerman, Michael J. , Bos, J. Martijn

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16736 Get It

Introduction: The incidence and etiologies underlying sudden cardiac arrest (SCA) in the young are derived from population- and referral-based cohorts of young SCA survivors. The extent to which the use of these cohorts contributes to discrepancies in our understanding of SCA in the young is unknown. As such, we sought to determine and compare the spectrum of SCA etiologies observed in young SCA survivors evaluated at a single tertiary center on both a primary and referral basis. Methods: Retrospective review of 940 young SCA survivors evaluated between 1990 and 2017 was used to identify all individuals ≤ 50 years of age that experienced a SCA. SCA root cause was determined by review of the medical records and diagnoses classified as ischemic, primary electrical, structural, or unexplained. SCA survivors that initially presented to our institution were classified as primary, while those who presented for secondary evaluation received a referral classification. Results: Overall, 566 SCA survivors were identified (age at event 33 ± 14 years; 39% females). In comparison to primary SCA survivors, referral SCA survivors were younger at the time of SCA (39 ± 12 vs. 30 ± 14 years; p<0.0001) and less likely to experience pre-SCA symptoms (45% vs. 27%; p<0.0001). Among all SCA survivors, the most common etiologies were idiopathic ventricular fibrillation (27%), acute coronary syndrome (21%), long QT syndrome (10%), and hypertrophic (7%) and dilated (6%) cardiomyopathies. Ischemic etiologies were less common (45% vs. 25%; p<0.0001) and primary electrical disorders more common (6% vs. 23%; p<0.0001) in referral SCA survivors. Conversely, genetic heart diseases (hypertrophic cardiomyopathy, long QT syndrome, etc.) were over-represented in referral cases (8% vs. 29%; p<0.0001), whereas no difference was observed in the number of primary and referral SCAs that remained unexplained. Conclusion: This study demonstrates, for the first time, that differences in SCA root cause exist between young SCA survivors evaluated at the same tertiary medical center on a primary vs. referral basis. Ongoing comparison of SCA etiologies between primary and referral SCA survivors may help resolve discrepancies regarding the contribution of specific disorders to SCA in the young.